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Abstract 
Pathogenic sequence variants in the nuclear bile acid receptor FXR, encoded by NR1H4, have 
been reported in a small number of children with low-GGT cholestasis progressing to liver 
failure.  We describe three additional children from two unrelated families with cholestasis and 
liver failure due to pathologic variants in NR1H4.  One patient underwent liver transplantation 
and has had good clinical outcomes in six years of follow-up. While that patient has biochemical 
evidence of increased bile acid synthetic activity, he has not experienced post-transplant diarrhea 
or allograft steatosis, as has been reported among other transplanted patients. 
 
Keywords:  pediatric, coagulopathy, bile acids, jaundice, hyperbilirubinemia 
 
What is known? 
 Pathogenic sequence variants in NR1H4 are associated with low-GGT cholestasis and 
liver failure. 
 Liver transplantation may offer effective rescue of liver failure, but transplanted patients 
might have residual biochemical and clinical abnormalities owing to extrahepatic FXR 
expression. 
What is new? 
 A strict genotype-phenotype correlation may not exist for this condition. 
 Increased bile acid synthesis observed among transplanted patients is not universally 
associated with evidence of allograft injury. 
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Introduction 
An advance in our understanding of intrahepatic cholestasis came when the molecular 
underpinnings of the syndromes known as progressive familial intrahepatic cholestasis (PFIC) 
type 1, PFIC2, and PFIC3 were found to be due to pathogenic variants in ATP8B1, ABCB11, and 
ABCB4, respectively.  In 2014, pathogenic variants in TJP2 were linked to low-GGT cholestasis 
and termed PFIC4 [1].  In 2016, four patients in two families with low-GGT cholestasis 
progressing to liver failure were described as having loss-of-function mutations in the nuclear 
bile acid receptor FXR, encoded by NR1H4, a disease subsequently designated PFIC5 [2] .  
Since then, only one additional child with PFIC5 has been reported [3] .  Herein, we describe 
three additional children from two unrelated families with cholestasis and liver failure due to 
pathologic variants in NR1H4. 
Family 1, Patient 1 
A 17-month-old Hispanic male was brought to medical attention for jaundice and abdominal 
distention.  He was the product of an uncomplicated term pregnancy to a 22-year-old 
primigravida.  The patient was normally developing; there was no family history of liver disease, 
however, the child’s parents were consanguineous. 
On examination, the patient appeared well-nourished (weight 79
th





 centile), jaundiced, and his abdomen was distended, with liver and spleen 
palpable ~5 cm below the costal margins.  Initial laboratory testing is shown in Table 1.  
Abdominal ultrasonography demonstrated splenomegaly and chest radiography revealed 
generalized osteopenia, but no evidence for fractures. 
A diagnostic evaluation was unrevealing, so a liver biopsy was performed which showed 
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micronodular cirrhosis and complete absence of BSEP protein along the canaliculus (Figure 1), 
while MDR3 expression was preserved, raising the possibility of ABCB11-related PFIC2.  
ABCB11 gene sequencing, however, was normal. 
The patient was treated with parenteral vitamin K, ursodeoxycholic acid, spironolactone, and 
lactulose. He was hypoglycemic while feeding orally, so dextrose-containing intravenous fluids 
were initiated along with nasogastric tube feedings.  After two weeks, his weight gain was 
suboptimal and he continued to require intravenous dextrose, so parenteral nutrition was started.  
He was evaluated and approved for liver transplantation, undergoing deceased donor liver 
transplant 11 weeks after his initial presentation, at 20 months of age.  Laboratory testing just 
before transplant reflected deterioration (Table 1).  His post-operative course included systemic 
hypertension and development of posterior reversible encephalopathy syndrome, which was 
treated with a change from tacrolimus to sirolimus, antihypertensives, and an antiepileptic.  He 
had an episode of early acute cellular rejection which was treated satisfactorily with steroids. 
Four years after the patient was transplanted, Gomez-Ospina et al described NR1H4 sequence 
variants in patients with low-GGT, intrahepatic cholestasis [2].  Because their patients exhibited 
lack of BSEP staining on liver immunohistochemistry, but no evidence for pathologic ABCB11 
sequence variants, like our patient, we pursued trio whole exome sequencing.  A homozygous 
pathogenic variant in NR1H4 (c.526C>T, p.R176X) was found in the proband and confirmed to 
be in trans-configuration.  Immunostain on retained explanted liver showed complete absence of 
FXR expression in hepatocytes (Figure 1). 
Six years post-transplant, the patient has continued to do well clinically.  He has not experienced 
diarrhea and somatic growth is normal.  Liver indices have been stably normal on sirolimus 
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monotherapy.  Four liver biopsies in the first two post-transplant years showed no significant 
steatosis. Assessment of the bile acid synthesis pathway revealed normal total cholesterol (124 
mg/dL), elevated 7-alpha-OH-4-cholesten-3-one (C4) (0.81 µmol/L, nl 0.02-0.05 µmol/L) and 
chenodeoxycholic acid (0.78 µmol/L, nl 0.07-0.23 µmol/L), but normal cholic acid (0.11 
µmol/L, nl 0.03-0.25 µmol/L). 
Family 2, Patient 2 
A 1-month-old female of Persian descent presented with jaundice, poor growth, and respiratory 
distress associated with a pleural effusion.  She was the full-term product of a consanguineous 
(first cousins) union.  Initial laboratory testing is shown in Table 1.  Diagnostic tests showed 
normal thyroid stimulating hormone, 17-OH-progesterone, galactose-1 phosphate uridyl 
transferase, succinylacetone, and biotinidase.  There was no biochemical evidence for disorders 
of β-oxidation of fatty acids, carnitine metabolism, organic acidemia, or urea cycle defects.  
Plasma amino acid profile showed elevations of tyrosine, methionine and galactose interpreted as 
reflective of hepatic dysfunction. 
She experienced a progressive course with increasing jaundice, hypoglycemia, and 
hyperammonemia (Table 1).  She died at 8-months-of-age due to multiorgan failure. 
Family 2, Patient 3 
Two-and-a-half years later, a 1-week-old male of the same union was admitted with jaundice, 
poor growth, and respiratory distress.  Like his sister, he was born at term and appeared well at 
birth.  Exam revealed the liver and spleen palpable 2 cm below the costal margins.  Initial 
laboratory testing is shown in Table 1.  Ultrasound of the right upper quadrant was normal, 
however, ultrasound of the chest showed a large, right, pleural effusion.  Diagnostic evaluation 
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reveled elevated plasma tyrosine.  No succinylacetone was detected, however, and genetic 
testing for tyrosinemia was also normal.  The patient was treated supportively with autologous 
serum therapy, fresh frozen plasma, and supplemental fat-soluble vitamins, but experienced 
progressive deterioration (Table 1).  Whole exome sequencing was performed which 
demonstrated a homozygous, out-of-frame insertion, in NR1H4 (c.276dupT, p.P93Sfs*4).    He 
died at 7-months-of-age due to liver failure. 
Discussion 
We have described 3 patients from 2 unrelated families with NR1H4 disease.  In contrast to most 
reported patients, Patient 1 had a later onset of illness (16 months) and failure-to-thrive was not a 
presenting sign.  However, like other patients, his course was marked by progressive jaundice, 
low GGT, vitamin K-refractory coagulopathy, and absence of BSEP staining on liver tissue.  
Patient 1 has the same homozygous NR1H4 variant reported in Family 1 from the Gomez-Ospina 
paper, in which both patients had much earlier onset, so a strict genotype-phenotype correlation 
may not exist.  Patient 1 also underwent liver transplantation but has not developed allograft 
steatosis or liver test abnormalities, in spite of having elevated plasma bile acid precursor C4 
post-transplantation, like the transplanted patients in the literature.  The increase in bile acid 
synthesis in these allografts likely relates to loss of FGF19-mediated feedback inhibition on 
hepatic CYP7A1 stemming from residual loss of the NR1H4 gene product (FXR) in the native 
intestine.  Patient 1 provides additional evidence that extrahepatic (e.g. gut, kidney) NR1H4 may 
not be essential since he has not developed a clinical abnormality in either organ system more 
than 6 years post-transplant. 
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Regarding Family 2, Patients 2 and 3 presented with strikingly similar clinical features and both 
succumbed to progressive liver disease before the 1
st
 birthday.  While less clinical and laboratory 
data was available for these patients, what is reported is consistent with other patients in the 
literature.  The nature of the pleural effusions in these patients, as well as those in the literature 
[2] , is not entirely clear, but that it was documented on the right side in Patient 3, may suggest 
hepatic hydrothorax, a common finding among patients with cirrhosis.  Patient 2 died before 
definitive molecular diagnostics could be obtained, however, whole exome sequencing of Patient 
3 demonstrated a novel, homozygous, out-of-frame insertion in NR1H4 (c.276dupT, p.P93Sfs*4) 
which is predicted to lead to premature termination of protein translation. 
NR1H4-related PFIC5 is a rapidly progressive disease, the natural history of which is not 
modified by medical interventions.  Liver transplantation, on the other hand, appears to provide a 
satisfactory outcome, with reasonably long follow-up among the small number of patients who 
have been transplanted.  While this is reassuring, it seems prudent to counsel families of children 
with PFIC5 being considered for liver transplantation about the extrahepatic expression of 
NR1H4 as well as the unknowns of gut-liver signaling following transplantation.  Based on the 
broad differential diagnosis for these patients and limited time in which to make important 
therapeutic decisions, we would advocate for early use of NR1H4 sequencing, or unbiased 
molecular diagnostics like whole exome sequencing, provided results can be available to the 
clinical team promptly. 
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Figure 1- Liver immunostain.  BSEP normal control (A), and explant of Patient 1 (B).  FXR 
normal control (C), and explant of Patient 1 (D). 
  
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
Table 1 Summary of clinical and laboratory findings 
  
Family 1 Family 2 
Patient 1 Patient 2 Patient 3 
Sex Male Female Male 
Age at onset 16 months 3 weeks 1 week 
Age at initial 
evaluation 
17 months 1 month 29 days 
Age at liver 
transplant 
20 months NA NA 
Age at last 
evaluation 








Jaundice, FTT, respiratory 



















(nl <0.3 mg/dL) 
11.3 37 5 8.3 8 8.3 
AST (nl <60 U/L) 627 291 71 200 78 193 
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ALT (nl <45 U/L) 383 302 49 69 51 71 
GGT (nl 10-19 
U/L) 
81 72 NM NM NM NM 
AFP (nl 8-468 
ng/mL) 
9,610 NM NM NM >100,000 NM 
Ammonia (nl 22-
48 µmol/L) 
64 84 NM NM 93 193 
Coagulation 
Parameters 
     
PT (nl 12.9-16.9 
sec) 
21.8 26.1 NM NM 15 NM 
INR (nl 0.9-1.1) 1.9 2.4 NM NM 1.25** NM 
Factor V Assay 
(nl 69-132%) 
38 26 NM NM NM NM 
Factor VII Assay 
(nl 58-150%) 





103 52 NM NM 308 190 
FTT failure to thrive; AST aspartate aminotransferase; ALT alanine aminotransferase; GGT, g-
glutamyl transferase; AFP alpha-fetoprotein; OLT, orthotopic liver transplant; PT prothrombin 
time; INR international normalized ratio; NA not applicable; MN not measured; nl normal; ** 
The values obtained were not representative due to transfusions of blood products.  
 
